Previous studies using DSG3-CAART or MuSK-CAART have demonstrated the preclinical feasibility and safety of antigen-specific B cell depletion in in vitro and in vivo models (10–12), leading to phase 1 clinical trials in mucosal pemphigus vulgaris and MuSK-MG. This evidence concerns the gene DSG3 and myasthenia gravis.